Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2015-07-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于维护公司股价稳定的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding measures to stabilize the company's stock price, including commitments from major shareholders and management not to reduce holdings, plans for share increases, and an employee stock ownership plan. It references regulatory notices and laws related to shareholder actions but does not contain financial statements, earnings data, or detailed financial analysis. The document is relatively short (836 characters) and serves as a public announcement about capital market actions and shareholder intentions rather than a financial report or detailed filing. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as shareholding commitments and stock stabilization measures.
2015-07-10 Chinese
关于控股股东减持股份暨完成减持计划的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the reduction of shares held by the controlling shareholder of Shenzhen Xintai Pharmaceutical Co., Ltd. It details the number of shares reduced, the method of reduction, the dates, and confirms compliance with relevant regulations. There is no financial report, earnings data, or management discussion. The content focuses on shareholding changes by a major shareholder, specifically the controlling shareholder's share reduction and completion of the reduction plan. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2015-05-22 Chinese
关于控股股东减持股份的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the reduction of shares held by the controlling shareholder of Shenzhen Xintai Pharmaceutical Co., Ltd. It details the number of shares reduced, the method of reduction (block trades), dates, and the shareholder's holdings before and after the reduction. It also confirms compliance with relevant regulations and prior disclosures. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of a shareholder's transaction in the company's shares, specifically a reduction in holdings by a major shareholder. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2015-05-20 Chinese
关于参与发起设立人寿保险股份有限公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding its participation in the establishment of a life insurance company. It details the investment overview, policy background, market prospects, risks, and impact on the company. The document includes a board resolution and references regulatory approvals but does not contain financial statements or detailed financial data. The length is about 3,144 characters, which is relatively short and the content is focused on an investment announcement rather than a financial report or earnings release. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a regulatory certification or officer attestation. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant investment and corporate action that does not fit other specific categories.
2015-04-24 Chinese
第三届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Shenzhen Xinlitai Pharmaceutical Co., Ltd. It details the decision made by the board to participate in establishing a life insurance company, including authorization to the general manager to sign related agreements. The document is short (826 characters) and serves as a formal disclosure of the board's decision rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is clearly a Board/Management Information announcement about a board resolution and authorization.
2015-04-24 Chinese
2014年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an 'Annual Equity Distribution Implementation Announcement' for the year 2014 by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the approved profit distribution plan, including cash dividends and capital reserve fund stock transfers, with specific dates for record, ex-dividend, and dividend payment days. It references the shareholders' meeting approval and provides detailed information on dividend amounts, share capital changes, and shareholder eligibility. The document is an announcement of the implementation of the equity distribution (dividend and stock split) plan rather than the full annual report or financial statements. It is relatively short (3188 characters) and focuses on dividend distribution details. Therefore, it fits the category of 'Notice of Dividend Amount' (DIV) rather than an Annual Report or other financial filings.
2015-04-16 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.